Name | Number of supported studies | Average coverage | |
---|---|---|---|
peripheral blood | 19 studies | 48% ± 13% | |
lung | 17 studies | 37% ± 11% | |
intestine | 11 studies | 31% ± 13% | |
kidney | 7 studies | 37% ± 10% | |
eye | 6 studies | 27% ± 9% | |
lymph node | 6 studies | 45% ± 11% | |
brain | 5 studies | 25% ± 4% | |
pancreas | 4 studies | 32% ± 14% | |
bone marrow | 4 studies | 29% ± 13% | |
placenta | 4 studies | 22% ± 10% | |
uterus | 4 studies | 47% ± 10% | |
breast | 4 studies | 42% ± 4% | |
liver | 4 studies | 45% ± 20% | |
prostate | 3 studies | 23% ± 8% |
Tissue | GTEx Coverage | GTEx Average TPM | GTEx Number of samples | TCGA Coverage | TCGA Average TPM | TCGA Number of samples |
---|---|---|---|---|---|---|
esophagus | 100% | 5815.18 | 1445 / 1445 | 100% | 66.76 | 183 / 183 |
ovary | 100% | 7771.12 | 180 / 180 | 100% | 90.93 | 430 / 430 |
skin | 100% | 6314.11 | 1809 / 1809 | 100% | 147.71 | 472 / 472 |
thymus | 100% | 6083.32 | 653 / 653 | 100% | 232.18 | 605 / 605 |
uterus | 100% | 7391.79 | 170 / 170 | 100% | 147.24 | 459 / 459 |
brain | 100% | 4055.61 | 2637 / 2642 | 100% | 191.50 | 705 / 705 |
adrenal gland | 100% | 5387.02 | 258 / 258 | 100% | 121.02 | 229 / 230 |
liver | 100% | 2140.28 | 225 / 226 | 100% | 93.86 | 406 / 406 |
kidney | 100% | 4685.28 | 89 / 89 | 100% | 111.48 | 897 / 901 |
intestine | 100% | 6170.54 | 966 / 966 | 99% | 110.86 | 524 / 527 |
prostate | 100% | 5351.56 | 245 / 245 | 99% | 136.22 | 498 / 502 |
stomach | 100% | 5100.90 | 359 / 359 | 99% | 89.71 | 283 / 286 |
lung | 100% | 5324.53 | 577 / 578 | 99% | 108.47 | 1140 / 1155 |
pancreas | 99% | 3705.84 | 325 / 328 | 99% | 135.60 | 177 / 178 |
bladder | 100% | 6303.95 | 21 / 21 | 98% | 129.41 | 496 / 504 |
breast | 100% | 7213.55 | 459 / 459 | 98% | 107.88 | 1092 / 1118 |
adipose | 100% | 7229.74 | 1204 / 1204 | 0% | 0 | 0 / 0 |
blood vessel | 100% | 6545.53 | 1335 / 1335 | 0% | 0 | 0 / 0 |
eye | 0% | 0 | 0 / 0 | 100% | 302.68 | 80 / 80 |
lymph node | 0% | 0 | 0 / 0 | 100% | 315.93 | 29 / 29 |
muscle | 100% | 8479.98 | 803 / 803 | 0% | 0 | 0 / 0 |
spleen | 100% | 6858.57 | 241 / 241 | 0% | 0 | 0 / 0 |
tonsil | 0% | 0 | 0 / 0 | 100% | 149.56 | 45 / 45 |
ureter | 0% | 0 | 0 / 0 | 100% | 106.00 | 1 / 1 |
peripheral blood | 99% | 5421.37 | 924 / 929 | 0% | 0 | 0 / 0 |
heart | 98% | 3343.08 | 844 / 861 | 0% | 0 | 0 / 0 |
abdomen | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
bone marrow | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
diaphragm | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
gingiva | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nasal cavity | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nasopharynx | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nose | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
placenta | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
spinal column | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
GO_0032435 | Biological process | negative regulation of proteasomal ubiquitin-dependent protein catabolic process |
GO_2000157 | Biological process | negative regulation of ubiquitin-specific protease activity |
GO_1904293 | Biological process | negative regulation of ERAD pathway |
GO_1903094 | Biological process | negative regulation of protein K48-linked deubiquitination |
GO_0043161 | Biological process | proteasome-mediated ubiquitin-dependent protein catabolic process |
GO_0031397 | Biological process | negative regulation of protein ubiquitination |
GO_0005634 | Cellular component | nucleus |
GO_0005654 | Cellular component | nucleoplasm |
GO_0034098 | Cellular component | VCP-NPL4-UFD1 AAA ATPase complex |
GO_0005783 | Cellular component | endoplasmic reticulum |
GO_0005829 | Cellular component | cytosol |
GO_0005737 | Cellular component | cytoplasm |
GO_1904855 | Molecular function | proteasome regulatory particle binding |
GO_0031625 | Molecular function | ubiquitin protein ligase binding |
GO_0036435 | Molecular function | K48-linked polyubiquitin modification-dependent protein binding |
GO_0051117 | Molecular function | ATPase binding |
GO_0031593 | Molecular function | polyubiquitin modification-dependent protein binding |
GO_0071796 | Molecular function | K6-linked polyubiquitin modification-dependent protein binding |
GO_0005515 | Molecular function | protein binding |
GO_0043130 | Molecular function | ubiquitin binding |
Gene name | UBXN1 |
Protein name | UBX domain protein 1 UBXN1 protein (cDNA FLJ30270 fis, clone BRACE2002661, highly similar to UBA/UBX 33.3 kDa protein) UBX domain-containing protein 1 (SAPK substrate protein 1) (UBA/UBX 33.3 kDa protein) |
Synonyms | SAKS1 LOC51035 hCG_1818009 |
Description | FUNCTION: Ubiquitin-binding protein that plays a role in the modulation of innate immune response. Blocks both the RIG-I-like receptors (RLR) and NF-kappa-B pathways. Following viral infection, UBXN1 is induced and recruited to the RLR component MAVS. In turn, interferes with MAVS oligomerization, and disrupts the MAVS/TRAF3/TRAF6 signalosome. This function probably serves as a brake to prevent excessive RLR signaling . Interferes with the TNFalpha-triggered NF-kappa-B pathway by interacting with cellular inhibitors of apoptosis proteins (cIAPs) and thereby inhibiting their recruitment to TNFR1 . Prevents also the activation of NF-kappa-B by associating with CUL1 and thus inhibiting NF-kappa-B inhibitor alpha/NFKBIA degradation that remains bound to NF-kappa-B . Interacts with the BRCA1-BARD1 heterodimer and regulates its activity. Specifically binds 'Lys-6'-linked polyubiquitin chains. Interaction with autoubiquitinated BRCA1 leads to the inhibition of the E3 ubiquitin-protein ligase activity of the BRCA1-BARD1 heterodimer . Component of a complex required to couple deglycosylation and proteasome-mediated degradation of misfolded proteins in the endoplasmic reticulum that are retrotranslocated in the cytosol. . |
Accessions | ENST00000533000.5 Q04323 E9PRQ7 Q05BV2 ENST00000529640.5 E9PS08 ENST00000616865.4 ENST00000301935.10 [Q04323-1] E9PJ81 A0A087WTZ5 ENST00000534176.1 ENST00000294119.6 [Q04323-2] |